Table 2 Description of clinical features of studies

Lan et al. [7]

CR, CSM

Zero-p

8/7

10/12

13/11

4/3

23.68 ± 1.93

24.39 ± 2.00

Vaishnav et al. [8]

NS

Zero-p

2/1

2/3

8/5

12/13

NS

NS

Wei et al. [11]

CR, CSM

Zero-p

5/6

8/21

15/32

9/9

15.3 ± 5.2

15.1 ± 5.2

He et al. [16]

CR, CSM

ROI-C

22.6 ± 3.3

27.1 ± 3.5

Noh et al. [17]

CR

Zero-p

8/8

19/24

11/14

37.6 ± 5.91

37.1 ± 15.7

Lee et al. [18]

CR

Zero-p

4/1

2/4

13/9

4/4

12.57 ± 2.09

28.89 ± 20.24

Son et al. [19]

CR

Zero-p

3/2

4/6

10/14

4/5

 ≥ 6

 ≥ 6

Nemoto et al. [20]

CR

PREVAIL

2/2

4/6

10/10

6/6

24

24

Wang et al. [21]

CSM

Zero-p

33.59 ± 5.52

33.16 ± 5.97

Li et al. [22]

CR, CSM

Zero-p

11/9

9/11

3/3

24

24

Wang et al. [23]

CSM

Zero-p

2/3

8/7

9/12

8/8

35.2

35.5

Yan et al. [24]

CR, CSM

Zero-p

12/13

25/22

15.32 ± 2.13

14.26 ± 2.35

Li et al. [25]

CR, CSM

Zero-p

5/7

10/10

9/10

81.0 ± 4.4

79.0 ± 3.4

Liu et al. [26]

CSM

Zero-p

3/2

9/13

13/11

6/5

15.52 ± 1.93

16.10 ± 2.33

Shao et al. [27]

NS

Zero-p

2/4

24/27

31/36

6/9

23.6 ± 4.5

25.2 ± 4.8

Yi et al. [28]

CR, CSM

Zero-p

 > 12

 > 12

Wang et al. [29]

CR, CSM

Zero-p

2/5

6/8

4/6

NS

NS

Guo et al. [30]

CR, CSM

Zero-p

13/10

9/13

9/9

10/12

9/5

18.5 ± 17.5

18.5 ± 17.5

Sun et al. [31]

CR, CSM

ROI-C

3–24

3–24

Hu et al. [32]

CR, CSM

ROI-C

15.7 ± 2.4

15.7 ± 2.4

Sha et al. [33]

CR, CSM

ROI-C

8/7

10/11

12/13

13.5 ± 1.5

13.5 ± 1.5

Chang et al. [9]

CSM

Zero-p

3/4

10/12

5/5

3/3

12–16

12–16

Ruan et al. [34]

CSM

ROI-C

0/1

2/4

12/8

7/5

13.3 ± 1.9

14.9 ± 1.7

Zhu et al. [35]

CR, CSM

ROI-C

> 12

 > 12

Zhang et al. [36]

CR, CSM

ROI-C

7/11

17/23

23/25

9/8

21.46 ± 4.51

21.46 ± 4.51

Gou et al. [10]

CSM

Zero-p

2/1

5/4

7/6

2/5

6–18

6–18

Luo et al. [37]

CR

Zero-p

5/3

9/10

23/22

13/15

 ≥ 24

 ≥ 24